2022
Clinical Management of Opioid Withdrawal
Torres‐Lockhart K, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical Management of Opioid Withdrawal. Addiction 2022, 117: 2540-2550. PMID: 35112746, DOI: 10.1111/add.15818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderOpioid withdrawal managementOpioid withdrawalClinical managementWithdrawal managementLong-term treatmentAppropriate clinical managementPatient-centered approachRelapse prevention strategiesHarm reduction strategiesHigh-risk timeOUD treatmentAppropriate diagnosisOpioid overdoseUse disordersPrevention strategiesTreatment settingsNarrative reviewWithdrawalTreatmentComplex casesManagementRelapsePatientsOverdose
2017
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMood disordersDeficiency hypothesisInitiation of therapyRapid antidepressant effectsRapid acting antidepressantsEvidence-based treatmentsLong-term riskMood disorders researchRelapse prevention strategiesEfficient therapeutic targetMechanism of actionOral antidepressantsAntidepressant effectsGlutamatergic receptorsGlutamatergic systemNovel antidepressantsSingle doseClinical trialsKetamine exposureRelated symptomsLong-term effectsPsychiatric disordersPrevention strategiesTherapeutic targetDrug AdministrationProgesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study
Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA. Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology 2017, 86: 96-103. PMID: 28926762, PMCID: PMC5659923, DOI: 10.1016/j.psyneuen.2017.09.012.Peer-Reviewed Original ResearchConceptsPre-pregnancy smokingSmoking levelsWeek 8Progesterone levelsPlacebo-controlled pilot trialDouble-blind studyOral micronized progesteroneSerious adverse eventsWeeks of gestationMain outcome measuresHalf of womenEndogenous progesterone levelsRelapse prevention strategiesCurrent pilot studyPreliminary findingsPostpartum smokersMicronized progesteronePlacebo groupProgesterone groupProgesterone replacementEligible womenSecondary outcomesAdverse eventsPoint prevalencePostpartum women
2015
How Imaging Glutamate, γ‐Aminobutyric Acid, and Dopamine Can Inform the Clinical Treatment of Alcohol Dependence and Withdrawal
Hillmer AT, Mason GF, Fucito LM, O'Malley SS, Cosgrove KP. How Imaging Glutamate, γ‐Aminobutyric Acid, and Dopamine Can Inform the Clinical Treatment of Alcohol Dependence and Withdrawal. Alcohol Clinical And Experimental Research 2015, 39: 2268-2282. PMID: 26510169, PMCID: PMC4712074, DOI: 10.1111/acer.12893.Peer-Reviewed Original ResearchConceptsAlcohol dependenceΓ-aminobutyric acidClinical treatmentMajor public health issuePublic health issuePositron emission tomographyRelapse prevention strategiesSingle photon emissionSpecific imaging modalityAlcohol withdrawalTobacco smokingGABA systemNeurotransmitter systemsNeurochemical basisPrevention strategiesDopaminergic functioningEmission tomographyHealth issuesImaging modalitiesWithdrawalSex differencesImaging literatureDopamineTomographyGlutamate
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply